Skip to search boxSkip to navigationSkip to main content

Metformin effectively treats Tsc1 deletion-caused kidney pathology by upregulating AMPK phosphorylation

  • Yili Fang
    ,
  • Fang Li
    ,
  • Chenyang Qi
    ,
  • Xing Mao
    ,
  • Feng Wang
    ,
  • Zhonghua Zhao
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>Tuberous sclerosis complex (TSC) is characterized by hamartomatous lesions in multiple organs, with most patients developing polycystic kidney disease and leading to a decline of renal function. TSC is caused by loss-of-function mutations in either Tsc1 or Tsc2 gene, but currently, there is no effective treatment for aberrant kidney growth in TSC patients. By generating a renal proximal tubule-specific Tsc1 gene-knockout (Tsc1<sup>ptKO</sup>) mouse model, we observed that Tsc1<sup>ptKO</sup> mice developed aberrantly enlarged kidneys primarily due to hypertrophy and proliferation of proximal tubule cells, along with some cystogenesis, interstitial inflammation, and fibrosis. Mechanistic studies revealed inhibition of AMP-activated protein kinase (AMPK) phosphorylation at Thr-172 and activation of Akt phosphorylation at Ser-473 and Thr-308. We therefore treated Tsc1<sup>ptKO</sup> mice with the AMPK activator, metformin, by daily intraperitoneal injection. Our results indicated that metformin increased the AMPK phosphorylation, but decreased the Akt phosphorylation. These signaling modulations resulted in inhibition of proliferation and induction of apoptosis in the renal proximal tubule cells of Tsc1<sup>ptKO</sup> mice. Importantly, metformin treatment effectively prevented aberrant kidney enlargement and cyst growth, inhibited inflammatory response, attenuated interstitial fibrosis, and protected renal function. The effects of metformin were further confirmed by in vitro experiments. In conclusion, this study indicates a potential therapeutic effect of metformin on Tsc1 deletion-induced kidney pathology, although currently metformin is primarily prescribed to treat patients with type 2 diabetes.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Article number

52

Journal (Volume, Issue Number)

Cell Death Discovery (Volume 6, Issue 1)

Publication milestones

  • Published - 12/01/2020

Publication status

Published - 12/01/2020

Publication IDs

  • Scopus: 85086471833

Publication metrics

Metrics

SciVal
FWCI
1.30
SciVal
Author count
9
SciVal
citations
4
SciVal
Paper percentile
88
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
23
Citation count
18

Funding Details

This work was supported by grants from the Science and Technology Commission of Shanghai Municipality (No. 15140902900).
FunderFunding number
STCSM
15140902900